Cidara Therapeutics Receives $20M Credit Facility from Square 1 Bank

cidaratheraCidara Therapeutics, Inc. (Nasdaq:CDTX), a San Diego, CA-based biotechnology company, entered into an agreement for a $20m credit facility with Square 1 Bank, a division of Pacific Western Bank.

Proceeds from the facility will provide working capital to support the company’s CD101 and CD201 programs which are in development to treat serious fungal and multi-drug resistant bacterial infections.

Led by Jeff Stein, Ph.D., president and CEO, Cidara is a clinical-stage biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections.
The company is currently advancing its novel echinocandin antifungal, CD101, through Phase 2 studies in two indications and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant bacterial infections.
In details:
– CD101 IV is a once-weekly therapy intended for the treatment and prevention of invasive fungal infections.
– CD101 topical is an agent being studied for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection.
– CD201 is a drug candidate selected from Cidara’s novel Cloudbreak™ platform, an immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.



Join the discussion